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Abstract 
Objectives: Network meta-analysis (NMA) methods extend the standard pair-wise framework to 
allow simultaneous comparison of multiple interventions in a single statistical model.  Despite 
published work on NMA mainly focussing on the synthesis of aggregate data (AD), methods have 
been developed that allow the use of individual patient-level data (IPD) specifically when outcomes 
are dichotomous or continuous.  This paper focuses on the synthesis of IPD and AD time to event 
data, motivated by a real data example looking at the effectiveness of high compression treatments 
on the healing of venous leg ulcers. 
 
Methods: This paper introduces a novel NMA modelling approach that allows IPD (time to event 
with censoring) and AD (event count for a given follow-up time) to be synthesised jointly by 
assuming an underlying, common, distribution of time to healing.  Alternative model assumptions 
were tested within the motivating example.  Model fit and adequacy measures were used to 
compare and select models. 
 
Results: Due to the availability of IPD in our example we were able to use a Weibull distribution to 
describe time to healing; otherwise, we would have been limited to specifying a uniparametric 
distribution.  Absolute effectiveness estimates were more sensitive than relative effectiveness 
estimates to a range of alternative specifications for the model. 
 
Conclusions: The synthesis of time to event data considering IPD provides modelling flexibility, and 
can be particularly important when absolute effectiveness estimates, and not just relative effect 
estimates, are of interest. 
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1. Background 
In clinical practice, and at a wider societal level, treatment decisions in medicine need to consider all 
relevant alternative health care technologies.  Such decisions are ideally informed by evidence on 
the relative effectiveness of treatments generated by randomised controlled trials (RCTs) (which 
may be further used to inform estimates of cost-effectiveness).  Using evidence from individual RCTs 
may limit informed decision making since studies usually only provide comparative evidence on two 
treatments, potentially missing other relevant technologies which are also treatment options.  This 
limitation can be overcome if all RCTs evaluating interventions relevant to the treatment decision 
are considered collectively, for example, with the use of network meta-analysis (NMA).  NMA is a 
well-established statistical technique that extends standard the pairwise meta-analysis framework to 
allow simultaneous comparison of multiple interventions in a single statistical model.  (1, 2) This 
approach then produces relative effect estimates (and associated descriptions of uncertainty) for all 
treatments connected by the network of evidence  ? even where head-to-head trials for comparisons 
do not exist (indirect data).  
 
NMA using individual patient data 
Published work on NMA mainly focuses on the synthesis of aggregate data (AD) (sometimes called 
summary data, e.g. group means and standard errors available from study reports) (3, 4); however, 
methods have been developed that allow use of individual patient-level data (IPD) in NMA (5-7).  The 
appeal of including IPD in a NMA is that it is likely to reduce statistical heterogeneity across the 
network (and in this way help resolve possible inconsistencies); and it may also allow for subgroup 
effects to be estimated that could guide more personalised treatment decisions (5).  The use of IPD, 
alone or in combination with AD, has been shown to improve inference in NMAs where the outcome 
of interest is dichotomous (or binary) by aiding convergence, and by providing unbiased treatment ?
covariate interactions [that would otherwise be affected by ecological bias (8)].  For continuous 
outcomes, IPD is likely to also lead to more precise estimates of treatment effects, even in the 
absence of treatment ?covariate interactions (9).  
 
NMA using time to event related outcome data 
Where individual studies present hazard ratios, these AD can be pooled directly using standard 
methods (analogous to pooling count data where relative effectiveness measures are the odds ratios 
or relative risks) (10).  However, other AD outputs such as median/mean time to event (11) and 
cumulative counts of patients having the outcome event in a period of time (12) have also been 
meta-analysed in a network  ? by specifying an underlying time to event distribution hazard ratios 
can be generated from these outputs (13).  Whereas IPD having been used in pairwise analysis (12), 
there has been limited development of methods in the NMA framework. 
 
Developing a NMA combining AD and IPD data to synthesise time to event related outcomes  
This paper describes a modelling framework that combines AD and IPD in the synthesis of time to 
event related outcomes.  This work was motivated by a NMA for which we had data from multiple 
RCTs comparing treatments for the healing venous leg ulcers.  A proportion of the RCT data was 
available in IPD format (time to event and time to censoring), with the remaining data available as 
AD, i.e. count data.  To maximally draw from the available data we aimed to statistically synthesise 
jointly the available AD and IPD, in this way generating better estimates and providing fuller 
characterisations of uncertainty to best inform decisions on the use of the treatments of interest. 
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2. Motivating example: high compression treatments for venous leg ulcers 
dŚĞĐĂƐĞƐƚƵĚǇƌĞůĂƚĞƐƚŽĐŽŵƉƌĞƐƐŝŽŶƐǇƐƚĞŵƐĂŝŵŝŶŐƚŽĚĞůŝǀĞƌŚŝŐŚĐŽŵƉƌĞƐƐŝŽŶ  ?ĐůĂƐƐĞĚĂƐш ? ?
mmHg compression at the ankle) to promote venous leg ulcer healing.  Available standardised 
systems are: two layer hosiery (HH), the four layer bandage (4LB), the short stretch bandage (SSB), 
the zinc paste bandage (ZINC), and the two layer bandage system (2LB).  A detailed description is 
provided in Box A1 in Appendix with further details of these systems presented elsewhere (14). 
 
Effectiveness evidence from RCTs was obtained from the most recent update of the relevant 
Cochrane review available to us (15), and from a recent multicentre RCT which compared 4LB with 
HH.  All available RCT evidence was assessed for inclusion in the current NMA: a detailed process 
that has been reported elsewhere (14).  The final NMA contained data from 16 RCTs on the relative 
effectiveness of high compression systems for the treatment of venous leg ulcers.  Data for two of 
the 16 included RCTs (VenUS I and VenUS IV, hereby denominated studies 1 and 2) had full IPD data 
available (841 participants) which included time to healing or censoring for each participant, 
together with other individual-level characteristics such as treatment centre, ulcer duration and size 
and also patient mobility.  For the remaining RCTs (1105 participants), aggregate data on the number 
of healed ulcers were extracted from the source review alongside information regarding treatment 
type, number of participants allocated to each treatment group, mean duration of follow-up (if this 
was not stated, trial duration was used), mean ulcer duration and size.   
 
The 16 included RCTs described nine unique high compression treatments: the five standard 
treatments (4LB, SSB, ZINC, HH and the 2LB) and four ad hoc systems (14).  The ad hoc group 
consisted of treatments deemed irrelevant to current clinical practice, and are not reported further 
(results can be provided upon request).  These studies were, however, included in the NMA as their 
data may still be relevant, for example, in describing determinants of healing.  
 
Table 1 describes the data available and Figure 1 presents the network between treatments formed 
by the evidence (14, 16-30).  The most populated comparison was the 4LB vs. SSB comparison, 
informed by seven RCTs: six available as AD (16-20, 29) and one IPD (30).  The link between the 2LB 
and 4LB was informed by two RCTs and each of the remaining six comparisons in the NMA were 
informed by AD extracted from one RCT for each comparison (Table 1).  
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Table 1: Analytic dataset 
ID 
Study 
Treatment 
Follow 
up 
(weeks) 
Number 
patients 
Mean 
duration 
(months) 
Mean 
size 
(cm
2
) 
Number 
healed 
Evidence 
format 
available 
16 Duby et al 1993 
(16)
 4LB 12 25 20.5 11.9 11 
AD 
  SSB 12 25 26.7 13.1 10 
17 Scriven et al 1998 
(17)
 4LB 52 32 13 13.3 17.6 
AD 
  SSB 52 32 21 8.3 18.24 
18 Partsch et al 2001 
(18)
 4LB 16 53 1.25 1.5 33 
AD 
  SSB 16 59 1 1.9 43 
19 Ukat et al 2003 
(19)
 4LB 12 44 -- 17.7 13 
AD 
  SSB 12 45 -- 12.2 10 
20 Franks et al 2004 
(20)
 4LB 24 74 2 5 59 
AD 
  SSB 24 82 2 3.5 62 
21 Junger et al 2004b 
(21)
 SSB 12 60 5.57 5.95 19 
AD 
  HH 12 61 4.14 5.62 29 
22 Kralj et al 1996 
(22)
 4LB 24 20 7.9 18.6 7 
AD 
  Ad hoc: Ba 24 20 6.9 17.2 8 
23 
Polignano et al 2004b 
(23)
 
4LB 24 39 -- 10.1 29 
AD 
  ZINC 24 29 -- 9.3 19 
24 
Wilkinson et al 1997 
(24)
 
4LB 12 17 -- 11.2 8 
AD 
 
 
Ad hoc: 
BHeH 
12 18 -- 8.6 8 
25 Colgan et al 1995 
(25)
 4LB 12 10 9.3 27.5 6 
AD 
 
 
Ad hoc: 
BzeaH 
12 10 66.5 48.5 7 
26 Blecken et al 2005 
(26)
 4LB 12 12 -- 50.08 4 
AD 
  Ad hoc: HV 12 12 -- 48.98 4 
27 Moffatt et al 2008 
(27)
 4LB 4 42 48.8 5.7 3 
AD 
  2LB 4 39 46.6 11.8 6 
28 
Szewczyk et al 2010 
(28)
 
4LB 12 15 -- 6 9 
AD 
  2LB 12 16 -- 5.3 10 
29 Wong et al 2012 
(29)
 4LB 24 107 -- -- 72 
AD 
  SSB 24 107 -- -- 77 
30 Iglesias et al 2004 
(30)
 4LB 52 195 3 3.81 107 
IPD 
  SSB 52 192 3 3.82 86 
14 Ashby et al 2013 
(14)
 4LB 52 224 12.29 9.30 157 
IPD 
  HH 52 230 10.82 9.41 163 
AD  ? aggregate-level data; IPD  ? individual patient data; 4LB, SSB, HH, Zinc paste,2LB and the ad hoc systems Ba,  BHeH, 
BzeaH, HV as described in Box A1 in Appendix 
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Figure 1: Network of RCTs 
In the network, a unique treatment category is indicated by a circle. Arrows between circles indicate that these 
ƚƌĞĂƚŵĞŶƚƐŚĂĚďĞĞŶĐŽŵƉĂƌĞĚŝŶĂƚƌŝĂů ?ƚƌŝĂůƐĂƌĞŝĚĞŶƚŝĨŝĞĚƵƐŝŶŐ ? ? ? ? ?ŶƵŵďĞƌĞĚĂƐŝŶĐŽůƵŵŶ ?/ ?ŝŶdĂďůĞ ? ?
(4LB, SSB, HH, Ba, Zinc paste,  BHeH, BzeaH, HV and 2LB as described in Box A1 in Appendix) 
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3. Methods 
We first describe in detail the modelling framework for our main analysis, model A.  We then detail 
the process of evaluating alternative assumptions to this model, thus highlighting and challenging 
specific assumptions of the modelling framework proposed.  All synthesis was conducted in a 
Bayesian framework. 
 
3.1. Statistical model for the data 
We describe model A in two interrelated parts [analogous to Sutton et al (31) and Saramago et al 
(5)]: part I describes the modelling of the IPD and part II the modelling of the AD.  
 
Model A, part I- modelling the IPD studies, controlling for baseline covariates 
 ݐ௜௝௞  ?ܹܾ݁݅ݑ݈݈൫ݏǡ ݄௜௝௞൯ܫ൫ݐ௜௝௞௖ ൯ ࢒࢕ࢍ൫ࢎ࢏࢐࢑ȁࢆ࢏࢐൯ ൌ ቊ ࣆ࢈ࡵࡼࡰ ൅ ࢽ࢐ࢉ ൅ ࢼ૙࢓  ? ࢆ࢏࢐ ࢈ ൌ ࡭ǡ࡮ǡ ࡯ǡǥ ࢑ ൌ ࢈ࣆ࢈ࡵࡼࡰ ൅ ࢊ࡭࢑ ൅ ࢊ࡭࢈ ൅ ࢽ࢐ࢉ ൅ ࢼ૙࢓  ? ࢆ࢏࢐  ࢆ࢏࢐ ?ࡺሺࢇ࢓ǡ ࢈࢓ሻ       ࢽ࢐ࢉ ?ࡺሺ૙ǡ ࣎ሻ       ࢽ ?ࡺሺ૙ǡ ࣎ሻ 
 
 
 
(A1) 
 
Time to ulcer healing (ݐ௜௝௞) of the ݅௧௛ participant in the ݆௧௛ study and in the ݇௧௛ treatment arm was 
assumed to be Weibull distributed  (32) with shape
1
 parameter, s, and scale parameter, ݄௜௝௞. For 
some participants, time to event was not observed, and these observations were censored at the 
time the participant last had trial data recorded, ݐ௜௝௞௖ . The baseline hazard function, linear on the log-
scale, was modelled as a function of the log-hazard of an event for the baseline treatment b, ߤ௕ூ௉஽, of 
treatment effects, ݀௕௞,  and of a set of baseline regression terms, ߚ଴௠  ? ௜ܼ௝, where ߚ଴௠
 
are the 
covariate effects of a set ܼ௜௝
 
of m (=4) regressors available in the IPD data sets (14): the log of the 
baseline ulcer area and duration (in months) (both centred around its mean value); and two dummy 
ǀĂƌŝĂďůĞƐ ? ?ǁĂůŬƐǁŝƚŚĚŝĨĨŝĐƵůƚǇ ?ĂŶĚ ?ŝŵŵŽďŝůĞ ? ?ƌĞĨĞƌƌŝŶŐƚŽƉĂƌƚŝĐŝƉĂŶƚŵŽďŝůŝƚǇ ?ƌĞĨĞƌĞŶĐĞĐĂƚĞŐŽƌǇ
ŝƐ ?ǁĂůŬƐĨƌĞĞůǇ ? ? ?dŚĞĞĨĨĞĐƚƐŽĨƚŚĞƐĞĐŽǀĂƌŝĂƚĞƐŽŶƚŚĞ hazard of healing were assumed to be equal 
in both IPD studies (i.e. the coefficient of each covariate was constant). Due to the existence of 
missing covariate information for some individuals, a distributional assumption was imposed on the 
covariate values, indicating that ܼ௜௝
 
are Normally distributed with mean ܽ௠ and precision ܾ௠, 
ĐŽŵŵŽŶĂĐƌŽƐƐĂůů/WƐƚƵĚŝĞƐ ?dŚŝƐƉƌŽĐĞĚƵƌĞĂƐƐƵŵĞƐƚŚĂƚƚŚĞŵŝƐƐŝŶŐŵĞĐŚĂŶŝƐŵǁĂƐ ?Ăƚ
ƌĂŶĚŽŵ ?2, which enables the use of multiple imputation techniques through MCMC3. Additionally, to 
account for centre variability within each IPD study, ߛ௝௖ was defined for each centre, c, in the ݆௧௛ 
study, these were combined using a common frailty effect, ߛ, described by a normal distribution 
with mean zero and precision ߬. 
 
The treatment effects, ݀௕௞, were log-hazard ratios for treatment k relative to the study-specific 
baseline treatment b, partitioned here as ݀௕௞ ൅ ݀஺௕. Prior distributions were specified for 
                                                 
1
 The shape parameter of the Weibull distribution, s, can be interpreted directly as follows: i) if 0 < s < 1, 
hazard rate decreases over time; ii) if s = 1, hazard rate is constant over time (hazard exponentially 
distributed); and if s > 1, it indicates that the hazard increases with time (Collet 2003). 
2
 The missing-at-random assumption (sometimes called the ignorability assumption) considers that the 
probability that an observation is missing may depend on the observed values but not the missing values, as 
sufficient data has already been collected. 
3
 When imputing missing information, MCMC generates independent draws of the missing data from its 
predictive distribution. Multiple imputation through MCMC techniques is attractive for exploratory or multi-
purpose analyses involving a large number of estimands. 
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ߤ௕ூ௉஽൫ ? ሺܰ ?ǡ ? ?଺ሻ൯, for each of the m regression coefficients ߚ଴൫ ? ሺܰ ?ǡ ? ?଺ሻ൯, for  ܽ௠൫ ? ሺܰ ?ǡ ? ?଺ሻ൯ and ܾ௠൫ ? ሺܰ ?ǡ ? ?଺ሻ൯, for the shared between centre variability ߬൫ ?ܩܽ݉݉ ሺܽ ?Ǥ ? ?ǡ ?Ǥ ? ?ሻ൯ and for ݏ൫ ?ܩܽ݉݉ ሺܽ ?Ǥ ? ?ǡ ?Ǥ ? ?ሻ൯. Vague prior distributions were given to ݀௕௞  ? ሺܰ ?ǡ ? ?଺ሻ. Note that ݀஺஺ ൌ  ?, where A was treatment 4LB, arbitrarily chosen as reference 
treatment. 
 
Model A, part II - modelling the AD studies 
 ݎ௝௞ ?ܤ݅ ൫݊݌௝௞ ǡ ௝݊௞൯ ݌௝௞ ൌ  ? െ ݁ݔ݌ቀെ ௝݄௞஺஽  ?൫ݐ௝௞஺஽൯௦ቁ ݈݋݃൫݄ ௝ܽ௞ȁ ௜ܺ௝൯ ൌ ቊ ߤ௝௕஺஽ ܾ ൌ ܣǡ ܤǡ ܥǡǥ ݇ ൌ ܾߤ௝௕஺஽ ൅ ݀஺௞ ൅ ݀஺௕  
 
 
 
 
(A2) 
 
Within the AD studies, the observed number of participants with a healed study ulcer, ݎ௝௞, from the 
total number of individuals in the ݆௧௛ trial and in the ݇௧௛ treatment arm (intention to treat), ௝݊௞, was 
assumed to be Binomially distributed. The underlying probabilities of an event for each arm and in 
each trial were represented by ݌௝௞. In turn, ݌௝௞  was expressed as a function of the hazard, ௝݄௞஺஽, of 
follow-up time, ݐ௝௞஺஽, and the shape parameter s. The hazard function, linear on the log-scale, was 
modelled by the baseline log-hazard of an event for treatment b in study j, ߤ௝௕஺஽, and by the log-
hazard ratio for treatment k and baseline treatment b, ݀௕௞ ሺൌ ݀஺௞ ൅ ݀஺௕ሻ. Note that there are 
parameters common to both model parts (equations A1 and A2), namely the log-hazard ratios and 
the shape parameter of the time to healing distribution. Prior distributions were specified for ߤ௝௕஺஽൫ ? ሺܰ ?ǡ ? ?଺ሻ൯. 
 
3.2. Alternative modelling assumptions 
A set of assumptions made within model A were challenged; these are detailed below.  
 
Exploring between-study variation  
Model A assumed that each included RCT aimed to measure a common treatment effect (fixed-
effect); however, it is likely that there was between-study variation. Model B included a random 
effect to characterise between-study heterogeneity, by considering ߜ௝௕௞  ? ሺܰ݀௕௞ ǡ ߪଶሻ ? ሺܰ݀஺௞ ൅݀஺௕ ǡ ߪଶሻ rather than just ݀௕௞  ? this is common to both parts I (eq. A1) and II (eq. A2). 
 
Time to healing distributions 
Model A used the Weibull distribution to describe time to healing.  Our choice of survival distribution 
was limited as distributions such as the Log-Logistic or the Log-Normal do not allow the probability 
of healing over time to be expressed in a closed form, and hence impede the approach proposed 
here for the joint synthesis of IPD and AD.  Other distributions, such as the Gompertz, were not 
readily defined within the software used in this work (WinBugs/OpenBugs), specifically under 
censoring.  Nonetheless, the goodness of fit could still be assessed in each IPD data source 
individually.  To do so, we applied parametric regression survival-time models (32) to both IPD data 
sources (16, 24) independently (covariates and frailty effect considered, as in model A). 
 
Distributional shape parameter  
Model A assumes that the Weibull shape parameter of the hazard of healing was common to both 
IPD data sources.  It is possible though that this parameter differed between studies, in which case 
hazard ratios could be affected.  Thus, we implemented two alternative NMA models to ascertain 
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the impact of this assumption on the relative effectiveness estimates: model C1 used the shape 
parameter from the first IPD study to describe the AD studies and model C2 used the shape 
parameter from the second IPD study (14) to describe these same studies.  Because models C1 and 
C2 represent simple modifications of model A we do not present these algebraically.  
 
Treatment-covariate associations 
Model A uses baseline covariates to adjust for clinical heterogeneity in the IPD.  To further explore 
the impact of covariates on the relative treatment effects (i.e. whether they were effect modifiers), 
and potentially help explain between-study heterogeneity, we also included interaction terms 
between alternative treatments and baseline ulcer area and duration ?  as described by Cooper et al 
2009 (33) and Saramago et al 2012 (5).  Model D assumed a regression (slope) coefficient for the 
interaction terms, this effect is common across treatments and thus common to parts I (eq. D1) and 
II (eq. D2).  This assumption was data driven, as this was the only option we were able to implement 
ǁŝƚŚƚŚĞĚĂƚĂĂǀĂŝůĂďůĞ ?ŝ ?Ğ ?ĐŽŵƉĂƌĞĚƚŽĂƐƐƵŵŝŶŐ ?ĞǆĐŚĂŶŐĞĂďŝůŝƚǇ ?Žƌ ?ŝŶĚĞƉĞŶĚĞŶĐĞ ? ?
 
(33).  Note 
that interaction estimates obtained are influenced by the full evidence base for which study mean 
covariate(s) values are available, including trials considering ad hoc treatments.  Given model D is 
substantially different to model A we describe it algebraically here.
 
 
Model D, part I- modelling the IPD studies  
 ݐ௜௝௞  ?ܹܾ݁݅ݑ݈݈൫ݏǡ ݄௜௝௞൯ܫ൫ݐ௜௝௞௖ ൯ ࢒࢕ࢍ൫ࢎ࢏࢐࢑ȁࢆ࢏࢐൯ ൌ ቊ ࣆ࢈ࡵࡼࡰ ൅ ࢽ࢐ࢉ ൅ ࢼ૙࢓  ? ࢆ࢏࢐ ࢈ ൌ ࡭ǡ࡮ǡ ࡯ǡǥ ࢑ ൌ ࢈ࣆ࢈ࡵࡼࡰ ൅ ࢊ࡭࢑ ൅ ࢊ࡭࢈ ൅ ࢽ࢐ࢉ ൅ ࢼ૙࢓  ? ࢆ࢏࢐ ൅ ࢼ࢔  ? ࢄ࢏࢐ ࢆ࢏࢐ ?ࡺሺࢇ࢓ǡ ࢈࢓ሻ       ࢽ࢐ࢉ ?ࡺሺ૙ǡ ࣎ሻ       ࢽ ?ࡺሺ૙ǡ ࣎ሻ 
 
(D1) 
 
Time to ulcer healing is modelled in the same way as in model A. A set of covariate-
treatment interaction regression terms, ߚ௡  ? ௜ܺ௝, are here defined, where ߚ௡ are the 
association effects, assumed common across studies and the same regardless of treatment 
(excluding control) , corresponding to a set ܺ௜௝ of n (=2) covariates including the log of the 
baseline ulceration area and baseline ulcer duration (in months). For the remainder of the 
parameters of interest, prior distributions were assigned as in model A.
 
 
 
Model D, part II - modelling the AD studies  
 ݎ௝௞ ?ܤ݅ ൫݊݌௝௞ ǡ ௝݊௞൯ ݌௝௞ ൌ  ? െ ݁ݔ݌ቀെ ௝݄௞஺஽  ?൫ݐ௝௞஺஽൯௦ቁ ݈݋݃൫݄ ௝ܽ௞ȁ ௜ܺ௝൯ ൌ ቊ ߤ௝௕஺஽ ܾ ൌ ܣǡ ܤǡ ܥǡǥ ݇ ൌ ܾߤ௝௕஺஽ ൅ ݀஺௞ ൅ ݀஺௕ ൅ ߚ௡  ? ௝ܺ 
 
௝ܺ  ?ܰሺ݁௠ǡ ݂௠ሻ 
 
(D2) 
 
The underlying probabilities of an event for each arm in each trial, ݌௝௞  , were regressed against n 
(=2) a set ௜ܺ௝  of study-level covariates [the log of the baseline ulceration area and baseline ulcer 
duration (in months)]. Uninformative prior distributions were assigned to the regression coefficients, ߚ௡൫ ? ሺܰ ?ǡ ? ?଺ሻ൯, to ݁௠൫ ? ሺܰ ?ǡ ? ?଺ሻ൯ and ݂௠൫ ? ሺܰ ?ǡ ? ?଺ሻ൯.  All other components of the model 
are as described for model A. 
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3.3. Model selection and implementation  
The NMA analyses were undertaken in the WinBUGs software (34).  In all models the MCMC sampler 
was run for 10 000 iterations and these were discarded as  ?ďƵƌŶ-ŝŶ ? ? Models were run for a further 
5000 iterations, on which inferences were based.  Chain convergence was checked.  The WinBUGS 
code is included for reference in the Appendix.  Within the NMA, goodness of fit was assessed using 
the deviance information criterion (DIC) (35).  Results were presented using hazard ratio estimates 
(and associated credibility intervals, CrIs) and also using the probability of each compression system 
ďĞŝŶŐƚŚĞ ?ďĞƐƚ ?ƚƌĞĂƚŵĞŶƚŝŶƚĞƌŵƐŽĨďĞŝŶŐƚŚĞŵŽƐƚĐůŝŶŝĐĂůůǇĞĨĨĞĐƚŝve (36). 
 
The statistical software STATA (37) was used to fit alternative time to event distributions to the IPD 
datasets individually.  Goodness of fit was assessed with the Akaike Information Criteria (AIC) 
statistic (38). 
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4. Results 
Table 2 shows parameter estimates obtained for model A (first column) and alternative models 
testing its assumptions (models B to D, second to fifth columns).  The results for model A highlight 
that the modelling framework proposed is feasible.  The results of testing the assumptions are 
described next, in turn. 
 
Exploring between-study variation  
Despite estimates of HRs from the random effect model (model B) being associated with wider CrIs 
than those from model A (as expected), point estimates were found to be fairly similar except for the 
comparison between HH vs. 4LB: HH is estimated to be more effective in model B (HR 1.63, 95% CrI 
0.76-3.53) compared to model A (HR: 1.05, 95% CrI 0.85 to 1.29), although the CrI of the former 
includes the later.  The treatment with the greatest estimated probability of healing was HH in 
model B (59%), rather than 2LB (72%) as in model A.  Differences may be explained by any existing 
variation between studies of SSB vs. 4LB indirectly impacting on the evidence loop 4LB vs. SSB vs. 
HH.  Baseline covariate effect estimates remained similar.  However, note that the gain in quality 
fitting of the random-effects model compared to the fixed-effects is null (DIC: 5396.21 and 5396.22, 
respectively).  Previous published work assessing evidence on the SSB vs. 4LB comparison (39) 
similarly found no evidence of between-study heterogeneity.  
 
Time to healing distributions 
The Weibull was the time to healing distribution used in model A.  Whilst we were limited in the use 
of other distributions, goodness of fit was explored by applying alternative time to event 
distributions to the IPD studies individually.  Table 3 shows results of such analysis (AIC statistic).  
The best fitting distributions for both studies were the Log-Logistic and Log-Normal.  Of the 
remaining, the Weibull and Gompertz distributions provided better fit than the Exponential; this was 
expected given the flexibility of these distributions in assuming increasing, decreasing or constant 
hazards over time.  The Weibull was best in IPD study 2 and the Gompertz best in IPD study 1.  
 
Distributional Weibull shape parameter of healing hazard  
The Weibull shape parameters estimated within models C1 and C2 indicate that in IPD study 1 (30) 
the hazard of healing was expected to decreases over time (sI = 0.93, 95% CrI 0.86-1.01), while in IPD 
study 2 (14) it is expected to increase (s2 = 1.27, 95% CrI 1.17-1.38).  Note that there is no overlap in 
the CrIs.  However, results show that relative effectiveness estimates are robust to the range of 
assumptions tested: the estimated HRs did not differ between models C1 and C2, and did not 
substantially differ from model A. 
 
Treatment-covariate associations 
Model D tested the inclusion of interaction terms. Results (column 5 of Table 2) found that the 
covariates included did not appear to be treatment effect modifiers in this case study.  However, 
estimating these two additional regression terms increased uncertainty in relative treatment effects 
estimates, specifically for ZINC and 2LB.  
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Table 2: Parameter estimates from the alternative MTC synthesis models. 
  
Model A Model B Model C1 Model C2 Model D 
Hazard ratios HR median (95% CrI) P HR median (95% CrI) P HR median (95% CrI) P HR median (95% CrI) P HR median (95% CrI) P 
                   
T
re
a
tm
e
n
t 
e
ff
e
ct
s 
  4LB --- --- 5.5 --- --- 1.4 --- --- 6.2 --- --- 5.7 --- --- 4.3 
  SSB 0.88 (0.76, 1.03) 0.4 0.96 (0.77, 1.22) 0.6 0.89 (0.77, 1.04) 0.6 0.89 (0.77, 1.04) 0.6 0.84 (0.70, 0.99) 0.2 
  HH 1.05 (0.85, 1.29) 16.1 1.63 (0.76, 3.53) 59.2 1.03 (0.83, 1.27) 14.9 1.03 (0.84, 1.27) 15.0 1.03 (0.84, 1.28) 11.1 
  ZINC 0.77 (0.41, 1.42) 6.2 0.78 (0.37, 1.62) 2.8 0.78 (0.41, 1.44) 6.5 0.78 (0.41, 1.43) 6.7 0.75 (0.03, 29.49) 17.5 
  2LB 1.40 (0.65, 3.05) 71.9 1.39 (0.62, 3.30) 36.0 1.38 (0.66, 3.05) 71.8 1.38 (0.63, 3.04) 72.0 1.59 (0.61, 5.34) 67.0 
 
                 
B
a
se
li
n
e
 
ch
a
ra
ct
e
ri
st
ic
s   Log area 0.71 (0.66, 0.76) --- 0.71 (0.66, 0.76) --- 0.70 (0.65, 0.75) --- 0.70 (0.65, 0.75) --- 0.71 (0.65, 0.76) --- 
  Log duration 0.92 (0.90, 0.94) --- 0.92 (0.90, 0.94) --- 0.92 (0.91, 0.94) --- 0.93 (0.91, 0.94) --- 0.92 (0.90, 0.94) --- 
  Difficulty in 
 walking 
0.71 (0.60, 0.85) --- 0.73 (0.60, 0.86) --- 0.72 (0.60, 0.85) --- 0.72 (0.60, 0.85) --- 0.71 (0.60, 0.80) --- 
  Immobile 0.67 (0.23, 1.52) --- 0.66 (0.23, 1.51) --- 0.72 (0.24, 1.65) --- 0.72 (0.25, 1.67) --- 0.68 (0.24, 1.59) --- 
 
                 
In
te
ra
 
ct
io
n
s   Log area --- --- --- --- --- --- --- --- --- --- --- --- 1.00 (0.97, 1.10) --- 
  Log duration --- --- --- --- --- --- --- --- --- --- --- --- 1.00 (0.99, 1.00) --- 
                  
  Btw-centre SD 0.04 (0.01, 0.13) --- 0.05 (0.01, 0.13) --- 0.05 (0.01, 0.15) --- 0.05 (0.01, 0.15) ---   ---  
                
  Btw-study SD --- --- --- 0.13 (0.01, 0.51) --- --- --- --- --- --- --- --- --- ---  
                
 
 ʄ;ƐͿ 1.07 (1.01, 1.13) --- 1.07 (1.01, 1.14) ʄ1** 0.93 (0.86, 1.01) ʄ1 0.93 (0.86, 1.01) --- 1.07 (1.01, 1.14) --- ʄ2 1.27 (1.17, 1.38) ʄ2** 1.27 (1.17, 1.38) 
  
                 
  DIC  5396.2 5396.2 5371.2 5371.5 5377.4 
                Model A  ? Fixed-effects NMA, Weibull model of IPD+AD; model B  ? Random-effects NMA, Weibull model of IPD+AD; model C1 - Fixed-effects NMA, Weibull model of IPD+AD, shape 
parameter derived from IPD study 1 only; model C2 - Fixed-effects NMA, Weibull model of IPD+AD, shape parameter derived from IPD study 2 only; model D - Fixed-effects NMA, Weibull 
model of IPD+AD, considering 2 treatment-effect modifiers 
** Shape parameter used in the synthesis model section for summary data. 
4LB = four layer bandage; SSB = Short stretch bandage; HH = two layer hosiery; 2LB = two layer bandage;  
HR = hazard ratios; CrI = credibility interval; SD = standard deviation; P = probability of being the best treatment choice in terms of healing (%); DIC  ? deviance information criteria 
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Table 3: Goodness of fit (AIC statistics) of alternative time to ulcer healing models for IPD studies 1 and 2. 
Time to event model 
Akaike Information Criteria (AIC) 
  IPD study 1 (22) 
 
IPD study 2 (14) 
       Weibull PH   1102.1 
 
1021.0 
Gompertz PH   1072.5 
 
1065.5 
Exponential PH   1102.7 
 
1068.4 
Log-Logistic AFT   1026.1 
 
971.8 
Log-Normal AFT   1032.2 
 
961.5 
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5. Discussion  
This paper introduces a novel NMA modelling approach that allows IPD (time to event with 
censoring) and AD (event count for a given follow-up time) to be synthesised jointly, by assuming an 
underlying, common, distribution of time to healing.  Available IPD is used directly to inform this 
distribution (likelihood).  Studies reporting the number of participants healed (AD) are used to 
inform a probability parameter, and a Binomial likelihood was defined for this subset of the 
evidence-set.  The probability of healing is then related (algebraically) to the common distribution of 
time to healing, by taking the duration of follow-up in each AD study into account.  This modelling 
framework extends the approaches of Soares et al (13) and Woods et al (40) and is also a natural 
extension of previously published methodologies of synthesising IPD and AD jointly (5, 31).  This 
work was motivated by a real data example looking at the effectiveness of high compression 
treatments on the healing of venous leg ulcers.  
 
We found that the key strength of the use of IPD in this context (additional to the known advantages 
described in the introduction) was the flexibility in modelling these data allowed.  For example, had 
all evidence been available as AD, the modelling process would have been limited to the 
specification of uniparametric distributions for time to healing [i.e. the Exponential, with constant 
healing hazard over time, as employed in Soares et al (13) and Woods et al (40)].  In our motivating 
example, the Exponential distribution was shown to be less adequate than other distributions in 
describing the time to event data in the studies for which IPD was available.  The availability of IPD 
allowed using a more complex distribution for time to event outcomes to be implemented, in this 
case the Weibull.  This may be of particular importance when absolute effectiveness estimates, and 
not just relative effect estimates, are of interest  ? and especially where results may need to be 
extrapolated beyond the follow-up time horizon.   
 
We note that even with this flexibility offered by the use of IPD we were, in practice, limited to using 
the Weibull distribution.  Given this limitation, the synthesis of time to event data will still often 
require the use of potentially suboptimal distributional assumptions, in which case estimates 
obtained may be biased.  We suggest further research, perhaps focuses on using numerical analysis 
techniques within the NMA, to try and resolve this issue.  
 
This work was also relevant to once more highlight the importance of considering IPD when wanting 
to either include baseline characteristics or control for treatment-effect modifiers.  The first relates 
to potential heterogeneity in the baseline hazard, which cannot be explicitly explored with AD only 
(this is important when analyses aim to explore determinants of baseline hazard, for example).  In 
doing so, and analogously to what is commonly undertaken in related methodologies such as IPD 
meta-analysis, in this study we assumed a common effect of baseline covariates on the hazard of 
healing across IPD studies.  The second relates to treatment-covariate interactions, that are 
generally acknowledged to be best estimated using IPD, as ecological bias can be avoided (8).  For 
the proportion of evidence only available as AD, the model here implemented considered study level 
mean covariate values.  Nonetheless, not all studies provided information for these, and imputation 
was undertaken (imputation is naturally ĚŽŶĞƚŚƌŽƵŐŚƚŚĞDD ?ĂŶĚĂƐƐƵŵĞƐǀĂůƵĞƐĂƌĞ ?ŵŝƐƐŝŶŐ
ĂƚƌĂŶĚŽŵ ? ? ? 
 
In our work we assumed the shape parameter of the Weibull time to event distribution to be 
common across studies. However, assumption testing proved this not to be valid, in this way 
highlighting the importance of evaluating any assumptions of similarity imposed across studies. 
Despite relative effectiveness estimates being mainly unaffected, such potential heterogeneity 
between studies should be explored and accounted for in analyses. Such assumptions of 
commonality also mean that information may be shared throughout the network, in which case 
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evidence on treatments other than those on our decision set (the five treatments of interest for 
which results were reported).  This is the case of model D that makes use of all evidence (including 
ad hoc treatments) to estimate treatment-covariate interaction, which may indirectly affect the 
relative effectiveness estimates of interest.  
 
In summary, by allowing flexibility in specifying survival distributions and in dealing and considering 
potential existing heterogeneity more fully (41), the use of IPD in a time to event outcome setting is 
particularly useful in guiding HTA decision making.  This work also emphasises the value of including 
anonymised IPD in evidence synthesis work.  There is increasing focus on promoting data sharing 
(42, 43) and this example highlights how use of IPD allows the development of more informative and 
flexible models that are better able to summarise existing evidence.  However, it is important to 
acknowledge that accessing and analysing IPD can be time consuming and may cause delay.  The 
process needs to be well planned and implemented.  In our case both sources of IPD were easily 
accessed and that directly facilitated the conduct of these analyses and the associated 
methodological work presented here. 
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Appendix  
Box A1: Description of main compression systems evaluated 
 
 
WiNBUGS code 
This code relates to model A described above and is here described in a generic form for it to be easy 
for the user to modify and adapt to specific applications.  Five datasets are required to fit the 
complete model: two containing constants for AD and IPD, two for both studies at IPD level and one 
for the AD evidence.  All data should be loaded before the model is compiled.  Because of size and 
agreements of use, the original data sets are not included in their entirety, but a couple of lines of 
data are supplied for each study/data combination for illustration purposes. 
 
model {  
### Part 1: Model for IPD 1 and IPD 2### 
for(i in 1:n.subjects1) { 
 #Weibull likelihood for IPD 1  
t.obs1[i] ~ dweib(shape,zu1[i])I(t.cen1[i],)  
 #Model for IPD 1 
log(zu1[i]) <- mu1 + betac1[centre1[i]] + d[treat1[i]] - d[baseline1[i]] +  
beta_cov * cov1[i] 
 cov1[i] ~dnorm(a1,b1) 
} 
 
#Vague priors for IPD 1 
mu1~dnorm(0,1.0E-6) 
a1~dnorm(0,1.0E-6) 
b1~dgamma(0.01, 0.01) 
for (i in 1:C1) {           
 betac1[i] ~ dnorm(0.0,taua) 
 } 
 
for(k in 1:n.subjects2) { 
 #Weibull likelihood for IPD 2  
 t.obs2[k] ~ dweib(shape,zu2[k])I(t.cen2[k],)  
 #Model for IPD 2 
 log(zu2[k]) <- mu2 + betac2[centre2[k]] + d[treat2[k]] - d[baseline2[k]] +  
beta_cov * cov2[i] 
1. Two layer hosiery, HH (smooth first layer, or understocking, providing light compression over which 
a second overstocking i.e. UK class II or III depending on the understocking slips on);  
2. Four layer bandage, 4LB (an elastic system consisting of an orthopaedic wool layer plus three 
subsequent bandages);  
3. Short stretch bandage, SSB (an inelastic bandage system where one to three rolls of bandage are 
applied over orthopaedic wool); 
4. Zinc paste bandage, ZINC (an inelastic system consisting of a paste bandage often with a support 
bandage on top);  
5. Two layer bandage system, 2LB (bottom layer with cohesive compression bandage - sub-
compression wadding layer and cohesive bandage).  
Network meta-analysis of (individual patient) time to event data alongside (aggregate) count data  19  
 
 
 
 cov2[i] ~dnorm(a2,b2) 
} 
 
#Vague priors for IPD 2 
mu2 ~ dnorm(0,1.0E-6) 
a2~dnorm(0,1.0E-6) 
b2~dgamma(0.01, 0.01) 
for (i in 1:C2) {           
 betac2[i] ~ dnorm(0.0,taua) 
 } 
 
#Vague priors for baseline patient characteristics effects 
beta_cov ~ dnorm(0,1.0E-6) 
 
# Part 2: Model for aggregate data # 
for(i in 1:n.agg.arm) { 
 #Binomial likelihood for AD 
 r[i]~dbin(pa[i],n[i]) 
 #Model for AD 
pa[i] <- 1 - exp( - zu.a[i] * pow(a.time[i], shape)) 
 log(zu.a[i]) <- mu.a[a.s[i]] + d[a.treat[i]] - d[a.base[i]] 
 } 
 
#Vague priors for AD 
for(j in 1:n.agg.trials) { 
 mu.a[j]~dnorm(0,1.0E-6) 
 } 
 
### Model for combining all estimates of treatment effect  # 
#Vague prior for shape parameter 
shape ~ dgamma(0.01, 0.01) 
#Vague priors for shared centre effect 
betac.new ~ dnorm(0.0,taua) 
taua ~ dgamma(0.01, 0.01) 
 
#Vague prior for basic parameters 
d[1]<-0 
for (k in 2:treat) { 
 d[k] ~ dnorm(0,1.0E-6) 
 } 
 
} 
 
### Dataset 1: Constants to define for IPD evidence### 
# Number of participants in IPD 1 # 
list(n.subjects1 = 386, 
# Number of participants in IPD 2 # 
n.subjects2 = 454,  
# Number of treatments being evaluated 
treat = 9, 
# Number of centres in IPD 1 
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C1 = 9,  
# Number of centres in IPD 1 
C2 = 35) 
 
### Dataset 2: Constants to define for AD evidence### 
# Number of AD studies # 
list(n.agg.trials = 14, 
# Number of AD study arms # 
n.agg.arms = 28) 
 
### Dataset 3: IPD 1 ### 
treat1[] baseline1[] t.obs1[] t.cens1[] cov1[] centre1[] 
1 1 3.50 0 1.95 3 
1 1 2.33 0 1.94 9 
2 1 NA 11.90 2.49 4 
... ...  ...  ...  ...  ...  
... ...  ...  ...  ...  ...  
END 
# treat1 = treatment arm (coded 1,2), baseline1 = reference treatment code,  
# t.obs1 = time to event in months (under censoring), t.cens1 = time of censoring in months, 
# cov1 = continuous covariate of interest (R+), centre1 = trial centre code (coded 1-9) 
 
### Dataset 4: IPD 2 ### 
treat2[] baseline2[] t.obs2[] t.cens2[] cov1[] centre2[] 
1 1 NA 21.28 5.15 1 
1 1 1.15 0 0.94 16 
3 1 8.41 0 2.31 2 
... ...  ...  ...  ...  ...  
... ...  ...  ...  ...  ...  
END 
# treat2 = treatment arm (coded 1,2), baseline2 = reference treatment code,  
# t.obs2 = time to event in months (under censoring), t.cens2 = time of censoring in months, 
# cov1 = continuous covariate of interest (R+), centre2 = trial centre code (coded 1-35) 
 
### Dataset 5: AD evidence ### 
a.s[] a.treat [] r[] n[] a.base[] a.time[] 
1 1 11 25 1 12 
1 2 10 25 1 12 
... ...  ...  ...  ...  ...  
... ...  ...  ...  ...  ...  
END 
# a.s = study number, a.treat = treatment arm code (coded from 1 to number of treatments),  
# r = number of events in trial arm, n = number of patients in trial arm, 
# a.base = reference treatment code, a.time = follow-up time of trial (in months) 
 
### Initial values, either need specifying or generating for the below scalars and vectors ### 
list(d = c(NA,0,0,0,0,0,0,0,0), mu1 = -1, mu2 = -1, mu.a = c(-1,-1,-1,-1,-1, -1,-1,-1,-1,-1, -1,-1,-1,-1),  
beta_cov = 0, shape = 1, betac.new = 0, betac1 = c(0,0,0,0,0, 0,0,0,0), betac2 = c(0,0,0,0,0, 0,0,0,0,0, 
0,0,0,0,0, 0,0,0,0,0, 0,0,0,0,0, 0,0,0,0,0, 0,0,0,0,0)) 
 
